1. Background {#sec58022}
=============

*Klebsiella pneumoniae* is an opportunistic pathogen responsible for up to 10% of all nosocomial infections ([@A11136R1], [@A11136R2]). These infections are often treated with extended-spectrum cephalosporins, fluoroquinolones and carbapenems. However, resistance mechanisms such as production of β-lactamases, plasmid-mediated quinolone resistance (PMQR) and carbapanemases by the organisms have created serious therapeutic problems ([@A11136R3]-[@A11136R5]).

PMQR determinants comprise; *Qnr*A, *Qnr*B, *Qnr*S, *Qnr*C and *Qnr*D proteins which protect DNA gyrase and topoisomerase IV from inhibition by quinolones; the aminoglycoside acetylteransferase variant, *aac (6')--Ib--cr*capable of acetylating and subsequently reducing the activity of norfloxacin and ciprofloxacin; and finally, the recently described flouroquinolone specific efflux pump protein, qepA ([@A11136R5]). Although PMQR determinants confer low level of quinolone resistance on their own, they have been shown to facilitate the acquisition of high level resistance among initially susceptible strains ([@A11136R6], [@A11136R7]).

PMQR determinants have been mostly identified in clinical isolates of *Enterobacteriaceae*, including *K. pneumoniae*, and have been shown to play not only an important role in quinolone resistance, but also resistance to other antibiotics, particularly β-lactams and aminoglycosides ([@A11136R8], [@A11136R9]). In fact, a number of studies have shown the presence of *qnr* genes along with various lactamases determinants on the same plasmids ([@A11136R10]-[@A11136R14]). Presence of PMQR genes in the community isolates of *K. pneumoniae* has also been shown, which provides a wider reservoir for the spread of these organisms ([@A11136R15]).

2. Objectives {#sec58023}
=============

We studied the presence of *qnr*A, *qnr*B, *qnr*S and *aac* (6')--*ib--cr* determinants among the cephalosporin and/or quinolone resistant community isolates of *K. pneumoniae*.

3. Materials and Methods {#sec58027}
========================

3.1. Bacteria {#sec58024}
-------------

Fifty-two *K. pneumoniae* isolates were collected from the Central laboratory in Karaj between July 2010 and January 2011 of which, 80.8% were from urine and 19.2% from stool samples. All isolates were identified by conventional biochemical and microbiological tests and were maintained in brain heart infusion broth (Oxoid, UK) containing 10% dimethyl sulfoxide (v/v) at -20ºC until use.

3.2. Antibacterial Susceptibility {#sec58025}
---------------------------------

Susceptibility to antibiotics was determined by the disc diffusion method using the CLSI recommendations and the following antibiotics (Himedia, India): amoxiclav (AMC, 20+10 µg), aztreonam (ATM, 30 µg), cefepime (CPM, 30 µg), cefotaxime (CTX, 30 µg), ceftazidime (CAZ, 30 µg), imipenem (IPM, 10 µg), ciprofloxacin (CP, 30 µg), levofloxacin (LOM, 5 µg), norfloxacin (NOR, 10 µg), ofloxacin (OFX, 5 µg) and nalidixic acid (NA, 30 µg). *K. pneumoniae* ATCC 10031 was used as the quality control for antimicrobial susceptibility tests.

3.3. DNA Extraction and PCR Amplification {#sec58026}
-----------------------------------------

DNA extraction was performed using an improved phenol/chloroform method where the lysis step was eliminated, and the cells were lysed directly by phenol ([@A11136R16]). Presence of *qnr*A, *qnr*B, *qnr*S, and *aac* (6')-*Ib-cr* genes was detected by PCR using the primers shown in [Table 1](#tbl14926){ref-type="table"} ([@A11136R12], [@A11136R17]). The reaction mixture (25 µl) contained 1.5 µl DNA template, 1.5 mM MgCl2, 0.25 mM of dNTP mix (Cinnagen, Iran), 1 unit of DFS-Taq DNA polymerase (Bioron, Germany), and 20 pmol of each primer (Faza Biothec, Iran). Amplifications were performed in a thermal cycler (Bioer TC25/H, Bioer Technolongy, China) using the following program: initial denaturation at 94ºC for 5 min followed by 30 cycles of 1 min at 94 ºC, 1 min at annealing temperature (57ºC for *qnr*A, *qnr*B and *qnr*S, 54ºC for *aac* (6')-*Ib-cr*), 1 min at 72ºC and a final extension period of 10 min at 72 C. The amplified PCR products were resolved by electrophoresis in 1.5% agarose gel and visualized after staining with ethidium bromide (Merck, Germany).

###### Primers Used For Detection of *qnr* and *aac* (6')-*Ib-cr* Genes

  Gene                  Primer Type   Primer Sequence           PCR Product Size   Reference
  --------------------- ------------- ------------------------- ------------------ ----------------
  ***qnrA***            Forward       TTCTCACGCCAGGATTTGAG      571 bp             ([@A11136R17])
                        Reverse       TGCCAGGCACAGATCTTGAC                         
  ***qnrB***            Forward       TGGCGAAAAAATTG*AAC*AGAA   594 bp             ([@A11136R17])
                        Reverse       GAGC*AAC*GATCGCCTGGTAG                       
  ***qnrS***            Forward       GACGTGCT*AAC*TTGCGTGAT    388 bp             ([@A11136R17])
                        Reverse       *AAC*ACCTCGACTTAAGTCTGA                      
  ***aac(6')-Ib-cr***   Forward       TTGCGATGCTCTATGAGTGGCTA   482 bp             ([@A11136R12])
                        Reverse       CTCGAATGCCTGGCGTGTTT                         

4. Results {#sec58030}
==========

4.1. Antibacterial Susceptibility {#sec58028}
---------------------------------

The antibiotic susceptibility results of the 52 *K. pneumoniae* isolates are shown in [Figure 1](#fig11629){ref-type="fig"}. All isolates were resistant to amoxilcav and susceptible to imipenem. Resistance rates to the other antibiotics were 13.5% to ceftazidime, cefotaxime and levofloxacin; 11.5% to cefepime; 7.7% to ciprofloxacin, nalidixic acid, and ofloxacin; and 5.8% to norfloxacin ([Figure 1](#fig11629){ref-type="fig"}). Twenty-three isolates were chosen for PCR studies based on their resistance to quinolones and/or cephalosporins.

![Antibiotic Resistance Profile of 52 *K. pneumoniae* Isolates Collected From Outpatients.\
NA: nalidixic acid, CP: ciprofloxacin, LOM: levofloxacin, NOR: norfloxacin, IPM: Imipenem, OFX: ofloxacin, AMC: amoxiclav, CTX: cefotaxime, CAZ: ceftazidime, CPM: cefepime.](jjm-07-11136-i001){#fig11629}

4.2. Detection of qnr and aac (6')-Ib-cr Determinants {#sec58029}
-----------------------------------------------------

[Figure 2](#fig11630){ref-type="fig"} shows the PCR amplification products of *qnr* and *aac* (6')-*Ib-cr* genes among the 23 selected isolates. Overall, 7 out of the 23 selected isolates harbored *qnr* and/or *aac* (6')-*Ib-cr* genes (30.4%), 6 of which were urinary isolates and 1, a stool isolate. None of the isolates harbored *qnr*A. Five isolates were resistant to all test quinolones and cephalosporins, of which, 3 carried *aac* (6')-*Ib-cr*, one had *qnr*S, and one carried both *aac* (6')-*Ib-cr* and *qnr*B genes. *Qnr*B was detected in 2 isolates both of which were quinolone and cephalosporin resistant. Two isolates harbored the *qnr*S gene; one of which was resistant to quinolones and cephalosporins and the other was quinolone susceptible, cephalosporin resistant. Finally, one quinolone susceptible, cephalosporin resistant isolate carried the *aac* (6')-*Ib-cr* gene.

![PCR Amplification Products of *qnr* and *aac* (6')-*Ib-cr* Genes\
A, *qnrB*; B, *qnrS* and C, *aac*(6')-*Ib-cr* genes in 23 community isolates of *K. pneumoniae*. L, 1 Kbp ladder; C-, negative control.](jjm-07-11136-g001){#fig11630}

5. Discussion {#sec58031}
=============

Presence of *qnr* and *aac* (6')-*Ib-cr* genes in clinical isolates of *E. coli* and *K. pneumoniae* has been reported worldwide ([@A11136R4]-[@A11136R9]). A large number of studies have also shown the presence of *qnr* genes along with resistance to various β-lactamases, including the AmpC and extended-spectrum β-lactamases ([@A11136R10], [@A11136R11], [@A11136R14], [@A11136R18], [@A11136R19]). However, studies on the presence of PMQR genes in the community isolates are far fewer. In the present study, majority of the community isolates of *K. pneumoniae* were susceptible to all test antibiotics except for amoxiclav. However, despite the low rate of antibiotic resistance, 13.5% of all test isolates and 30.4% of the quinolone and/or cephalosporin resistant isolates carried *qnr* and/or *aac* (6')-*Ib-cr* genes.

In a study conducted on *Escherichia coli* in Italy, the rate of *qnr* gene carriage was 27.8% of which; *aac* (6\')-*Ib-cr* was detected in 11% of the community isolates ([@A11136R20]). In another study conducted in northern Italy between 2004 and 2006, the *aac* (6\')-*Ib-cr* gene was found in 3.9% of the community isolates of the uropathogenic *E. coli* ([@A11136R21]). PMQR genes were also reported in commensal isolates of *Enterobacteriaceae* from Vietnam, including 45 *K. pneumoniae* isolates of which 35.5% carried the *qnr*S and *aac* (6\')-*Ib-cr* genes ([@A11136R22]). More recently, a study from Morocco showed that among 34 community isolates of *K. pneumoniae*, 41% harbored plasmid-mediated *qnr* genes, including *qnr*A, *qnr*B and *qnr*S, and 76.4% carried the *aac* (6\')-*Ib-cr* gene ([@A11136R15]). Our results were closer to the report from Vietnam but much lower than the Moroccan study. We did not detect the *qnr*A gene among our isolates. Although *qnr*A1 was the first PMQR gene discovered, several studies have indicated that *qnr*S, *qnr*B and *aac* (6')-*Ib-cr*) are more commonly found among*Enterobacteriaceae* ([@A11136R5], [@A11136R6], [@A11136R23]).

Consistent with the previous studies, we also showed the presence of *aac* (6\')-*Ib-cr*, *qnr*B, and *qnr*S genes but not *qnr*A among our community isolates. We believe that this is the first report on the presence of PMQR genes in *K. pneumoniae* isolates collected from outpatients in Iran. There is one other study from Iran where the prevalence of PMQR genes (*qnr*A and *qnr*B but not *qnr*S) was detected in *E. coli* ([@A11136R13]). Since quinolone resistant genes are plasmid-mediated, dissemination of these antibiotic resistance determinants could easily occur between opportunistic Gram-negative pathogens, which can be problematic and further limit treatment of these infections.
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**Implication for health policy/practice/research/medical education:**Presence of plasmid-mediated quinolone resistance (PMQR) genes in clinical isolates of *Enterobacteriaceae,* including *K. pneumoniae* have been shown to play an important role in quinolone resistance, as well as resistance to β-lactams and aminoglycosides. PMQR gene carriage in community isolates of *K. pneumoniae* is alarming and can provide a wide reservoir for the spread of these organisms.
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